These findings could also explain why past studies using GLI1 or SHH as biomarkers made controversial conclusions for the importance of HH pathway in NSCLC [16–21, 30], because the two factors are conditionally, but not constitutively activated. This evidence concerns the gene GLI1 and non-small cell lung carcinoma.